Febrile Neutropenia: The Oncology Emergency Behind a Simple Fever
A patient on chemotherapy phones the clinic: "It's just a temperature." Those four words trigger the fastest protocol a cancer hospital runs — blood cultures drawn and powerful antibiotics running within the hour. Why? Because in a body stripped of its neutrophils, an ordinary bug that a healthy person would shrug off can be lethal by morning. This is febrile neutropenia, and knowing what to do in the first sixty minutes saves lives.
Ten days ago she finished a cycle of chemotherapy. Tonight she feels a little hot — 38.3°C — nothing dramatic, no cough, no obvious source. She almost doesn't call. But she was warned, so she does. The nurse asks one question — "when was your last chemo?" — and the moment she hears "ten days", the tone changes. She is told to come in NOW, not in the morning. On arrival, before anyone knows a single culture result, two large IV lines go in, blood is drawn, and within forty minutes a broad-spectrum antibiotic is dripping into her arm. All of that for a low-grade fever. This is not overreaction — it is the whole discipline of neutropenic sepsis compressed into one hour.
The setup: chemotherapy, the nadir, and a body without guards
Cytotoxic chemotherapy does not spare the bone marrow. Most anticancer drugs kill rapidly dividing cells — and few cells divide faster than the myeloid precursors in the bone marrow that manufacture neutrophils. So a few days after treatment, neutrophil production collapses. The count falls, reaches its lowest point — the nadir — typically around 7 to 14 days after the dose, then slowly recovers before the next cycle. Neutrophils are the immune system's frontline soldiers against bacteria. When their number drops, the body loses its ability to contain infection, and the usual walls that wall off a bug simply are not built.
The definitions are worth memorizing because they trigger the whole response. Febrile neutropenia is diagnosed when a single oral temperature is ≥38.3°C, or ≥38.0°C sustained over one hour, AND the absolute neutrophil count (ANC) is below 0.5 × 10⁹/L — or below 1.0 and predicted to fall below 0.5. The lower the count and the longer it lasts, the higher the risk. Deep neutropenia (ANC < 0.1) lasting more than seven days is the danger zone.
The most dangerous feature of neutropenic sepsis is what is MISSING. With no neutrophils, the patient cannot mount the classic signs of infection — pus, redness, swelling, an infiltrate on the chest X-ray. A pneumonia may show almost nothing on film; an abscess may have no visible collection. Often the ONLY sign is the fever itself. Never reassure yourself with a "clean" examination in a neutropenic patient — the absence of signs is the disease, not its exclusion.
The golden hour: cultures, then antibiotics — do not wait
The single most important lesson in this entire topic is one of timing. A febrile neutropenic patient is treated as having sepsis until proven otherwise. The sequence is: take blood cultures (from a peripheral vein and, if present, from each lumen of a central line), do a rapid focused assessment — and then start broad-spectrum intravenous antibiotics IMMEDIATELY, empirically, within one hour of presentation. You do NOT wait for the culture result. You do NOT wait to confirm the neutrophil count if the clinical picture fits. The bug is already multiplying in a defenceless host; every hour of delay costs lives.
The empirical drug of choice is a single antipseudomonal beta-lactam (β-lactam) with broad Gram-negative cover. In practice that means piperacillin-tazobactam (Tazocin); alternatives are a carbapenem such as meropenem or imipenem, or the antipseudomonal cephalosporin cefepime or ceftazidime. Pseudomonas aeruginosa must always be covered because it can kill a neutropenic patient within hours. Monotherapy with one of these agents is the standard starting point — routinely adding an aminoglycoside to every patient is no longer recommended.
Not every patient needs the same second drug. The empirical β-lactam is the backbone; you escalate based on specific clues. Add a glycopeptide — vancomycin (or teicoplanin) — if there is a suspected central-line infection, skin or soft-tissue infection, haemodynamic instability, or known colonization with a resistant Gram-positive organism such as MRSA (methicillin-resistant Staphylococcus aureus). If the fever persists for four to seven days despite broad antibacterial cover and the patient remains neutropenic, add empirical antifungal therapy — an echinocandin such as caspofungin, or liposomal amphotericin B — to cover invasive fungal infection (notably Candida and Aspergillus). Antibiotics do not treat a fungus, and prolonged neutropenia is exactly when fungi invade.
- Fever + ANC < 0.5 × 10⁹/L = a medical emergency (neutropenic sepsis) until proven otherwise.
- Blood cultures first, then broad-spectrum IV antibiotics WITHIN ONE HOUR — never wait for results.
- First-line = antipseudomonal β-lactam: piperacillin-tazobactam, a carbapenem, or cefepime/ceftazidime.
- Add vancomycin/glycopeptide for line, skin, or MRSA-suspected infection or instability.
- Add empirical antifungal (caspofungin, liposomal amphotericin B) if fever persists 4–7 days.
- The classic signs of infection are usually absent — the fever may be the only clue.
Who needs a hospital? Risk stratification with the MASCC score
Not every febrile neutropenic patient is equally sick. Some are at high risk of serious complications and need admission and intravenous therapy; a carefully selected minority are at low risk and may, after initial assessment, be managed as outpatients on oral antibiotics. To make that call objectively, clinicians use the MASCC score (Multinational Association for Supportive Care in Cancer). It adds points for features such as minimal or no symptoms, no hypotension, no chronic obstructive pulmonary disease, a solid tumour (or no previous fungal infection), no dehydration, outpatient status, and younger age. A score of ≥ 21 identifies low-risk patients; a score below 21 flags high risk.
A carefully selected low-risk patient (MASCC ≥ 21, expected short neutropenia, stable, able to take oral drugs and return quickly if worse) may be treated with oral ciprofloxacin plus amoxicillin-clavulanate (co-amoxiclav) — a combination that still covers Pseudomonas and Gram-positives — with close follow-up. This is an option for the RIGHT patient, never a default. Any doubt about the risk category, any instability, or any social barrier to rapid return means admission and IV therapy.
Prevention: shortening the danger window
The best febrile neutropenia is the one that never happens. The deepest lever of prevention is to shorten the neutropenic period itself with granulocyte colony-stimulating factor (G-CSF) — filgrastim, or its long-acting pegylated form pegfilgrastim. These growth factors push the bone marrow to produce and release neutrophils faster, raising the count and shrinking the days spent below the danger threshold. Given as primary prophylaxis (starting with the chemotherapy cycle, before any fever) for regimens carrying a high risk of febrile neutropenia — conventionally a risk above roughly 20% — G-CSF measurably reduces the incidence, the depth, and the duration of neutropenia. The mechanism of these growth factors is covered in the Hematology growth-factors chapter.
The second lever is antimicrobial prophylaxis in selected high-risk patients — those expecting prolonged, profound neutropenia (for example after intensive haematological regimens or stem-cell transplant). This may include a fluoroquinolone (such as levofloxacin) to reduce Gram-negative bacterial infections, an antifungal (such as fluconazole or posaconazole) against invasive fungal disease, aciclovir against herpes simplex/zoster reactivation, and co-trimoxazole (trimethoprim-sulfamethoxazole) to prevent Pneumocystis jirovecii pneumonia (PCP). Prophylaxis is targeted, not universal — the antimicrobials themselves are detailed in the Antimicrobials section.
- G-CSF (filgrastim, pegfilgrastim) as PRIMARY prophylaxis shortens neutropenia for high-risk (>~20%) regimens.
- MASCC score ≥ 21 = low risk (possible oral/outpatient care); < 21 = high risk (admit, IV).
- Antimicrobial prophylaxis (fluoroquinolone, antifungal, aciclovir, co-trimoxazole for PCP) is for selected high-risk patients only.
- The nadir (lowest count) falls ~7–14 days post-chemo — the fever most often arrives in that window.
- G-CSF prevents; it is not a routine treatment of established uncomplicated febrile neutropenia.
- Waiting for the blood-culture result or the neutrophil count before starting antibiotics. Start empirically within one hour — the confirmation can come later.
- Expecting the classic signs of infection. A neutropenic patient may have only a fever — a normal-looking exam does NOT exclude serious sepsis.
- Forgetting G-CSF primary prophylaxis in high-risk regimens, then treating the febrile neutropenia that could have been prevented.
- Treating every patient as low-risk (or every patient as high-risk) instead of stratifying with a tool like the MASCC score.
A patient is 10 days post-chemotherapy with a temperature of 38.5°C and an ANC of 0.3 × 10⁹/L. The examination is unremarkable. What is the correct immediate action?
- Fever in a neutropenic patient (ANC < 0.5) is a medical emergency — treat as neutropenic sepsis until proven otherwise.
- Golden hour: cultures first, then empirical broad-spectrum IV antibiotics within one hour — never wait for results.
- First-line antipseudomonal β-lactam; add vancomycin for line/MRSA/instability, antifungal if fever persists 4–7 days.
- Stratify with the MASCC score; prevent with G-CSF primary prophylaxis and targeted antimicrobial prophylaxis in high-risk patients.
- Katzung BG. Basic & Clinical Pharmacology — Cancer chemotherapy: myelosuppression, the nadir & supportive care.
- NICE Guideline (NG191/CG151). Neutropenic sepsis: prevention and management in people with cancer.
- Freifeld AG, et al. IDSA Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer.
- Klastersky J, et al. The MASCC risk-index score for identifying low-risk febrile neutropenic patients.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Hematopoietic growth factors (G-CSF) & antimicrobial therapy.
